Please Wait.....
Report
Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets
Market Research Report I 2025-01-30 I 150 Pages I BCC Research
Description
Report Scope
This report provides an in-depth analysis of the global market for liquid biopsy tools, services and diagnostics, including market estimations and trends, using 2023 as the base year and forecasting 2024 through 2029 with a compound annual growth rate (CAGR) projection. The report includes an overview of the industry structure and its competitive landscape. Leading market players' profiles, product offerings, financial information and recent market activities are provided. The report also assesses companies' business strategies and their effect in the face of the competitive environment. It details the global market based on application, purpose of analysis, biomarker type and platform. Regional analysis includes North America (U.S., Canada, Mexico), Europe (U.K., Germany, France, Spain, Italy, Rest of Europe), Asia-Pacific (China, India, Japan, and Rest of Asia-Pacific), and the Rest of the world (South America, and the Middle East and Africa).
Report Includes
- 65 data tables and 58 additional tables
- Analyses of the trends in the global market for liquid biopsy research tools, services and diagnostics, with market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024, and projected CAGRs through 2029
- Estimates of the market size and revenue growth prospects, along with a market share analysis by application, purpose of analysis, biomarker type, analysis platform (technology type) and region
- Examination of conventional biopsy methods and liquid biopsy enabling technologies
- Discussion of large-scale research initiatives
- Facts and figures pertaining to key market dynamics, technology advances, regulations, and the impact of macroeconomic factors
- Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Patent analysis, including key granted and published patents
- Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Profiles of leading companies, including Exact Sciences Corp., Natera Inc., Guardant Health, Roche, and NeoGenomics Laboratories
Executive Summary
Summary:
Liquid biopsies are a particularly alluring substitute for or addition to tissue biopsies for applications in cancer, transplant medicine and reproductive health. Finding the biomarker that indicates the liquid biopsy's intended use-tumor (for cancer applications), fetus (for prenatal screening applications) or transplanted organ (for transplant medicine applications) is the goal of a liquid biopsy. A paradigm shift in medicine is brought about by liquid biopsy, which also offers enormous business prospects. These market niches hold great promises for cancer screening and early diagnosis, recurrence monitoring for cancer patients and non-invasive prenatal screening for average-risk populations.
Liquid biopsies offer substantial medical benefits when compared with traditional tissue-based biopsies. These benefits drive the adoption of liquid biopsy in the three major market segments: cancer, reproductive health and organ transplantation. For cancer, tissue biopsy is historically the standard of care. Needles, surgery or endoscopy are often used to perform tissue biopsies. Each of these methods poses potential risks to the patient. For example, a needle biopsy can result in several complications, including hemorrhage, hematoma, pneumothorax, puncture of nearby organs or tissues, infection, needle tract implantation or seeding of tumor cells. In addition, there is often pain and discomfort during a biopsy procedure.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Overview
Liquid Biopsy Versus Traditional Biopsy
Analytes Used in Liquid Biopsy
Emerging Clinical Applications of Liquid Biopsy
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Advances in Liquid Biopsy Workflow Technologies
Increasing Incidence of Cancer
Increasing Awareness of Early Cancer Detection
Limitations of Tissue Biopsy
Market Restraints
Lower Sensitivity of Certain Liquid Biopsy Procedures
Market Opportunities
Growing Significance of Precision Medicine
Emerging Economies such as China
Chapter 4 Emerging Technologies and Clinical Trials
Nanotechnology in Liquid Biopsy
Microfluidic-based Devices in Liquid Biopsy
Clinical Trials in Liquid Biopsy Market
Chapter 5 Market Segmentation Analysis
Market Trends
Segmentation Breakdown
Global Market for Liquid Biopsy by Application
Non-invasive Prenatal Testing (NIPT)
Cancer
Organ Transplantation
Global Market for Liquid Biopsy by Purpose of Analysis
Early Detection/Screening
Monitoring
Diagnosis
Therapy Guidance
Global Market for Liquid Biopsy by Biomarker Type
Cell-free Nucleic Acids
Circulating Tumor Cells
Other Biomarker Types
Global Market for Liquid Biopsy by Analysis Platform
Next-Generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Other Analysis Platforms
Global Market for Liquid Biopsy by Cancer Site
Pan-Cancer
Colorectal Cancer
Breast Cancer
Lung Cancer
Bladder Cancer
Prostate Cancer
Hematologic Cancer
Gynecologic Cancer
Other Cancers
Geographic Breakdown
Global Market for Liquid Biopsy by Region
North America
Europe
Asia-Pacific
Rest of the World (RoW)
Chapter 6 Competitive Intelligence
Ranking of Leading Players
Comparative Analysis
Chapter 7 Sustainability in the Liquid Biopsy Market: ESG Perspective
Introduction to ESG
ESG Practices in the Liquid Biopsy Industry
Environmental Performance
Social Performance
Governance Performance
ESG Risk Ratings
Concluding Remarks from BCC Research
Chapter 8 Appendix
Methodology
Abbreviations
References
Company Profiles
BIO-RAD LABORATORIES INC.
BIO-TECHNE
DXCOVER LTD.
EXACT SCIENCES CORP.
F. HOFFMANN-LA ROCHE LTD.
FREEENOME HOLDINGS INC.
GUARDANT HEALTH
ILLUMINA INC.
MYRIAD GENETICS INC.
NATERA INC.
NEOGENOMICS LABORATORIES
NOVIGENIX SA
PERSONALIS INC.
QIAGEN
THERMO FISHER SCIENTIFIC INC.
List of Tables
Summary Table B : Global Market for Liquid Biopsy, by Region, Through 2029
Summary Table A : Global Market for Liquid Biopsy, by Application, Through 2029
Table 1 : Liquid Biopsy Sample Types and Characteristics
Table 2 : Types of Analytes Used in Liquid Biopsy
Table 3 : Comparison of ctDNA/cfDNA and CTCs
Table 4 : List of Some Liquid Biopsy-based Available Tests Approved by FDA/CE-IVD
Table 5 : Global Cancer Incidence and Mortality Cases, by WHO Region, 2022
Table 6 : Emerging ctDNA and CTC Technologies for Liquid Biopsies
Table 7 : List of Clinical Trials Conducted in Liquid Biopsies
Table 8 : Global Market for Liquid Biopsy, by Application, Through 2029
Table 9 : Global Market for Liquid Biopsy for NIPT, by Region, Through 2029
Table 10 : Global Market for Liquid Biopsy for Cancer, by Region, Through 2029
Table 11 : Global Market for Liquid Biopsy for Organ Transplantation, by Region, Through 2029
Table 12 : Global Market for Liquid Biopsy, by Purpose of Analysis, Through 2029
Table 13 : Global Market for Liquid Biopsy for Early Detection/Screening, by Region, Through 2029
Table 14 : Global Market for Liquid Biopsy for Monitoring, by Region, Through 2029
Table 15 : Global Market for Liquid Biopsy for Diagnosis, by Region, Through 2029
Table 16 : Global Market for Liquid Biopsy for Therapy Guidance, by Region, Through 2029
Table 17 : Global Market for Liquid Biopsy, by Biomarker Type, Through 2029
Table 18 : Global Market for Liquid Biopsy for Cell-free Nucleic Acids, by Region, Through 2029
Table 19 : Global Market for Liquid Biopsy for Circulating Tumor Cells, by Region, Through 2029
Table 20 : Global Market for Liquid Biopsy for Other Biomarker Types, by Region, Through 2029
Table 21 : Global Market for Liquid Biopsy, by Analysis Platform, Through 2029
Table 22 : Global Market for Liquid Biopsy for Next-Generation Sequencing, by Region, Through 2029
Table 23 : Global Market for Liquid Biopsy for Polymerase Chain Reaction, by Region, Through 2029
Table 24 : Global Market for Liquid Biopsy for Other Analysis Platforms, by Region, Through 2029
Table 25 : Global Market for Liquid Biopsy, by Cancer Site, Through 2029
Table 26 : Global Market for Liquid Biopsy for Pan-Cancer, by Region, Through 2029
Table 27 : Global Market for Liquid Biopsy for Colorectal Cancer, by Region, Through 2029
Table 28 : Global Market for Liquid Biopsy for Breast Cancer, by Region, Through 2029
Table 29 : Global Market for Liquid Biopsy for Lung Cancer, by Region, Through 2029
Table 30 : Global Market for Liquid Biopsy for Bladder Cancer, by Region, Through 2029
Table 31 : Global Market for Liquid Biopsy for Prostate Cancer, by Region, Through 2029
Table 32 : Global Market for Liquid Biopsy for Hematologic Cancer, by Region, Through 2029
Table 33 : Global Market for Liquid Biopsy for Gynecologic Cancer, by Region, Through 2029
Table 34 : Global Market for Liquid Biopsy for Other Cancers, by Region, Through 2029
Table 35 : Global Market for Liquid Biopsy, by Region, Through 2029
Table 36 : North American Market for Liquid Biopsy, by Application, Through 2029
Table 37 : North American Market for Liquid Biopsy, by Purpose of Analysis, Through 2029
Table 38 : North American Market for Liquid Biopsy, by Biomarker Type, Through 2029
Table 39 : North American Market for Liquid Biopsy, by Analysis Platform, Through 2029
Table 40 : North American Market for Liquid Biopsy, by Cancer Site, Through 2029
Table 41 : Estimated Incidence of Cancer Cases in the EU, by Country, 2022
Table 42 : European Research Initiatives Focused on Personalized Medicine
Table 43 : European Market for Liquid Biopsy, by Application, Through 2029
Table 44 : European Market for Liquid Biopsy, by Purpose of Analysis, Through 2029
Table 45 : European Market for Liquid Biopsy, by Biomarker Type, Through 2029
Table 46 : European Market for Liquid Biopsy, by Analysis Platform, Through 2029
Table 47 : European Market for Liquid Biopsy, by Cancer Site, Through 2029
Table 48 : Asia-Pacific Market for Liquid Biopsy, by Application, Through 2029
Table 49 : Asia-Pacific Market for Liquid Biopsy, by Purpose of Analysis, Through 2029
Table 50 : Asia-Pacific Market for Liquid Biopsy, by Biomarker Type, Through 2029
Table 51 : Asia-Pacific Market for Liquid Biopsy, by Analysis Platform, Through 2029
Table 52 : Asia-Pacific Market for Liquid Biopsy, by Cancer Site, Through 2029
Table 53 : RoW Market for Liquid Biopsy, by Application, Through 2029
Table 54 : RoW Market for Liquid Biopsy, by Purpose of Analysis, Through 2029
Table 55 : RoW Market for Liquid Biopsy, by Biomarker Type, Through 2029
Table 56 : RoW Market for Liquid Biopsy, by Analysis Platform, Through 2029
Table 57 : RoW Market for Liquid Biopsy, by Cancer Site, Through 2029
Table 58 : Leading Companies in the Liquid Biopsy Market, 2023
Table 59 : Comparison of Liquid Biopsy Tests for Early Detection of Single Cancers
Table 60 : Key Focus Areas in ESG Metrics
Table 61 : Environmental Performance Initiatives in the Liquid Biopsy Market
Table 62 : Social Performance Initiatives in the Liquid Biopsy Market
Table 63 : Governance Performance Initiatives in the Liquid Biopsy Market
Table 64 : ESG Rankings for Leaders in the Market for Liquid Biopsy, 2024*
Table 65 : Abbreviations Used in this Report
Table 66 : Bio-Rad Laboratories Inc.: Company Snapshot
Table 67 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2022 and 2023
Table 68 : Bio-Rad Laboratories Inc.: Product Portfolio
Table 69 : Bio-Rad Laboratories Inc.: News/Key Developments, 2022-2024
Table 70 : Bio-Techne: Company Snapshot
Table 71 : Bio-Techne: Financial Performance, FY 2022 and 2023
Table 72 : Bio-Techne: Product Portfolio
Table 73 : Bio-Techne: News/Key Developments, 2023 and 2024
Table 74 : Dxcover Ltd.: Company Snapshot
Table 75 : Dxcover Ltd.: Product Portfolio
Table 76 : Dxcover Ltd.: News/Key Developments, 2023 and 2024
Table 77 : Exact Sciences Corp.: Company Snapshot
Table 78 : Exact Sciences Corp.: Financial Performance, FY 2022 and 2023
Table 79 : Exact Sciences Corp.: Product Portfolio
Table 80 : Exact Sciences Corp.: News/Key Developments, 2022-2024
Table 81 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 82 : F. Hoffman-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 83 : F. Hoffman-La Roche Ltd.: Product Portfolio
Table 84 : F. Hoffman-La Roche Ltd.: News/Key Developments, 2021-2023
Table 85 : Freenome Holdings Inc.: Company Snapshot
Table 86 : Freenome Holdings Inc.: Product Portfolio
Table 87 : Freenome Holdings Inc.: News/Key Developments, 2023 and 2024
Table 88 : Guardant Health: Company Snapshot
Table 89 : Guardant Health: Financial Performance, FY 2022 and 2023
Table 90 : Guardant Health: Product Portfolio
Table 91 : Guardant Health: News/Key Developments, 2022-2024
Table 92 : Illumina Inc.: Company Snapshot
Table 93 : Illumina Inc.: Financial Performance, FY 2022 and 2023
Table 94 : Illumina Inc.: Product Portfolio
Table 95 : Illumina Inc.: News/Key Developments, 2022 and 2023
Table 96 : Myriad Genetics Inc.: Company Snapshot
Table 97 : Myriad Genetics Inc.: Financial Performance, FY 2022 and 2023
Table 98 : Myriad Genetics Inc: Product Portfolio
Table 99 : Myriad Genetics Inc.: News/Key Developments, 2022-2024
Table 100 : Natera Inc.: Company Snapshot
Table 101 : Natera Inc.: Financial Performance, FY 2022 and 2023
Table 102 : Natera Inc: Product Portfolio
Table 103 : NeoGenomics Laboratories: Company Snapshot
Table 104 : NeoGenomics Laboratories: Financial Performance, FY 2022 and 2023
Table 105 : NeoGenomics Laboratories: Product Portfolio
Table 106 : NeoGenomics Laboratories: News/Key Developments, 2022-2024
Table 107 : Novigenix SA: Company Snapshot
Table 108 : Novigenix SA: Product Portfolio
Table 109 : Novigenix SA: News/Key Developments, 2024
Table 110 : Personalis Inc.: Company Snapshot
Table 111 : Personalis Inc.: Financial Performance, FY 2022 and 2023
Table 112 : Personalis Inc.: Product Portfolio
Table 113 : Personalis Inc.: News/Key Developments, 2023 and 2024
Table 114 : QIAGEN: Company Snapshot
Table 115 : QIAGEN: Financial Performance, FY 2022 and 2023
Table 116 : QIAGEN: Product Portfolio
Table 117 : QIAGEN: News/Key Developments, 2023 and 2024
Table 118 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 119 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
Table 120 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 121 : Thermo Fisher Scientific Inc.: News/Key Developments, 2022
List of Figures
Summary Figure A : Global Market for Liquid Biopsy, by Application, 2021-2029
Summary Figure B : Global Market for Liquid Biopsy, by Region, 2021-2029
Figure 1 : Snapshot of the Market Dynamics for Liquid Biopsy
Figure 2 : Global Market Shares of Liquid Biopsy, by Application 2024
Figure 3 : Global Market for Liquid Biopsy for NIPT, by Region, 2021-2029
Figure 4 : Estimated Number of New Cancer Cases Globally, 2022, 2045 and 2050
Figure 5 : Global Market for Liquid Biopsy for Cancer, by Region, 2021-2029
Figure 6 : Global Market for Liquid Biopsy for Organ Transplantation, by Region, 2021-2029
Figure 7 : Global Market Shares of Liquid Biopsy, by Purpose of Analysis, 2024
Figure 8 : Global Market for Liquid Biopsy for Early Detection/Screening, by Region, 2021-2029
Figure 9 : Global Market for Liquid Biopsy for Monitoring, by Region, 2021-2029
Figure 10 : Global Market for Liquid Biopsy for Monitoring, by Region, 2021-2029
Figure 11 : Global Market for Liquid Biopsy for Therapy Guidance, by Region, 2021-2029
Figure 12 : Global Market Shares of Liquid Biopsy, by Biomarker Type, 2024
Figure 13 : Global Market for Liquid Biopsy for Cell-free Nucleic Acids, by Region, 2021-2029
Figure 14 : Global Market for Liquid Biopsy for Circulating Tumor Cells, by Region, 2021-2029
Figure 15 : Global Market for Liquid Biopsy for Other Biomarker Types, by Region, 2021-2029
Figure 16 : Global Market Shares of Liquid Biopsy, by Analysis Platform, 2024
Figure 17 : Global Market for Liquid Biopsy for Next-Generation Sequencing, by Region, 2021-2029
Figure 18 : Global Market for Liquid Biopsy for Polymerase Chain Reaction, by Region, 2021-2029
Figure 19 : Global Market for Liquid Biopsy for Other Analysis Platforms, by Region, 2021-2029
Figure 20 : Global Market Shares of Liquid Biopsy, by Cancer Site, 2024
Figure 21 : Global Market for Liquid Biopsy for Pan-Cancer, by Region, 2021-2029
Figure 22 : Global Market for Liquid Biopsy for Colorectal Cancer, by Region, 2021-2029
Figure 23 : Global Market for Liquid Biopsy for Breast Cancer, by Region, 2021-2029
Figure 24 : Global Market for Liquid Biopsy for Lung Cancer, by Region, 2021-2029
Figure 25 : Global Market for Liquid Biopsy for Bladder Cancer, by Region, 2021-2029
Figure 26 : Global Market for Liquid Biopsy for Prostate Cancer, by Region, 2021-2029
Figure 27 : Global Market for Liquid Biopsy for Hematologic Cancer, by Region, 2021-2029
Figure 28 : Global Market for Liquid Biopsy for Gynecologic Cancer, by Region, 2021-2029
Figure 29 : Global Market for Liquid Biopsy for Other Cancers, by Region, 2021-2029
Figure 30 : Global Market Shares of Liquid Biopsy, by Region, 2024
Figure 31 : U.S. Elderly Population (65 and Older), 2010-2050
Figure 32 : North American Market for Liquid Biopsy, by Application, 2021-2029
Figure 33 : North American Market for Liquid Biopsy, by Purpose of Analysis, 2021-2029
Figure 34 : North American Market for Liquid Biopsy, by Biomarker Type, 2021-2029
Figure 35 : North American Market for Liquid Biopsy, by Analysis Platform, 2021-2029
Figure 36 : North American Market for Liquid Biopsy, by Cancer Site, 2021-2029
Figure 37 : European Market for Liquid Biopsy, by Application, 2021-2029
Figure 38 : European Market for Liquid Biopsy, by Purpose of Analysis, 2021-2029
Figure 39 : European Market for Liquid Biopsy, by Biomarker Type, 2021-2029
Figure 40 : European Market for Liquid Biopsy, by Analysis Platform, 2021-2029
Figure 41 : European Market for Liquid Biopsy, by Cancer Site, 2021-2029
Figure 42 : Asia-Pacific Market for Liquid Biopsy, by Application, 2021-2029
Figure 43 : Asia-Pacific Market for Liquid Biopsy, by Purpose of Analysis, 2021-2029
Figure 44 : Asia-Pacific Market for Liquid Biopsy, by Biomarker Type, 2021-2029
Figure 45 : Asia-Pacific Market for Liquid Biopsy, by Analysis Platform, 2021-2029
Figure 46 : Asia-Pacific Market for Liquid Biopsy, by Cancer Site, 2021-2029
Figure 47 : RoW Market for Liquid Biopsy, by Application, 2021-2029
Figure 48 : RoW Market for Liquid Biopsy, by Purpose of Analysis, 2021-2029
Figure 49 : RoW Market for Liquid Biopsy, by Biomarker Type, 2021-2029
Figure 50 : RoW Market for Liquid Biopsy, by Analysis Platform, 2021-2029
Figure 51 : RoW Market for Liquid Biopsy, by Cancer Site, 2021-2029
Figure 52 : How a Strong ESG Proposition Benefits Businesses?
Figure 53 : Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, FY 2023
Figure 54 : Bio-Rad Laboratories Inc.: Revenue Share, by Country/Region, FY 2023
Figure 55 : Bio-Techne: Revenue Share, by Business Unit, FY 2023
Figure 56 : Bio-Techne: Revenue Share, by Country/Region, FY 2023
Figure 57 : Exact Sciences Corp.: Revenue Share, by Business Unit, FY 2023
Figure 58 : Exact Sciences Corp.: Revenue Share, by Country/Region, FY 2023
Figure 59 : F. Hoffman-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 60 : F. Hoffman-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 61 : Guardant Health: Revenue Share, by Business Unit, FY 2023
Figure 62 : Guardant Health: Revenue Share, by Country/Region, FY 2023
Figure 63 : Illumina Inc.: Revenue Share, by Business Unit, FY 2023
Figure 64 : Illumina Inc.: Revenue Share, by Country/Region, FY 2023
Figure 65 : Myriad Genetics Inc.: Revenue Share, by Business Unit, FY 2023
Figure 66 : Myriad Genetics Inc.: Revenue Share, by Country/Region, FY 2023
Figure 67 : Natera Inc.: Revenue Share, by Country/Region, FY 2023
Figure 68 : NeoGenomics Laboratories: Revenue Share, by Business Unit, FY 2023
Figure 69 : Personalis Inc.: Revenue Share, by Business Unit, FY 2023
Figure 70 : QIAGEN: Revenue Share, by Business Unit, FY 2023
Figure 71 : QIAGEN: Revenue Share, by Country/Region, FY 2023
Figure 72 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2023
Figure 73 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2023
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security